Evidence map›Paper›PMID 23188837›Full record

ReviewBMJ case reports2012

Are increased Foxp3+ regulatory T cells responsible for immunosuppression during HTLV-1 infection? Case reports and review of the literature.

Nicolas Barros, Fernando Woll, Luis Watanabe, Martin Montes

Open access · greenAbstract readCase ReportsReview
In one paragraph

Review in BMJ case reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Human T-cell Leukemia Virus Type 1 andPathogens (Basel, Switzerland) · 2020
    Review
  3. Review
  4. Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2019
    Review
  5. Article
  6. Peripheral blood CD4Parasitology research · 2017
    Article
  7. Review
  8. Increased Numbers of CD4In vivo (Athens, Greece)
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Nicolas BarrosDepartment of Immunology, Instituto de Medicina Tropical 'Alexander von Humboldt', Universidad Peruana Cayetano Heredia, Lima, Peru.
Fernando Woll
Luis Watanabe
Martin Montes
Universidad Peruana Cayetano Heredia · PETexas Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Research of human T lymphotropic virus type I (HTLV-1)-associated diseases is mostly focused on inflammatory and lymphoproliferative disorders. However, the immunosuppressive consequences of HTLV-1 infection are frequently ignored. In developing countries where exposure to parasitic and other tropical diseases is frequent, the burden of disease is significantly increased by opportunistic infections. Regulatory T cells (Tregs) are a CD4 T-cell subset capable of suppressing effector responses. During HTLV-1 infection, CD4+Foxp3+ cells are increased in HTLV-1-associated leukaemia/lymphoma (ATLL) as well as in non-leukaemic presentations. However, controversy exists regarding the actual regulatory function of these cells. In this report, we present two cases of HTLV-1 ATLL complicated by parasitic organisms and we provide a brief review of the literature regarding FoxP3+ regulatory T cells and their role as a possible mechanism for the immunosuppressive manifestations that take place during HTLV-1 infection.

Indexed as

Entamoeba histolyticaStrongyloides stercoralisAgedAnimalsBiopsyCD4-Positive T-LymphocytesEntamoebiasisFatal OutcomeFemaleForkhead Transcription FactorsHTLV-I InfectionsHumansImmune ToleranceImmunoenzyme TechniquesLeukemia-Lymphoma, Adult T-CellMiddle AgedForkhead Transcription FactorsFOXP3 protein, human

Identifiers

PMID23188837
PMCPMC4543792
OpenAlexW2050376512

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.